Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ACADIA Pharmaceuticals stock in Canada

Own ACADIA Pharmaceuticals shares in just a few minutes.

ACADIA Pharmaceuticals is a biotechnology business based in the US. ACADIA Pharmaceuticals stocks (ACAD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.7 – an increase of 1.32% over the previous week. ACADIA Pharmaceuticals employs 570 staff and has a trailing 12-month revenue of around $474.4 million.

How to buy shares in ACADIA Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACAD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy ACADIA Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted ACADIA Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, ACADIA Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $23.05, which is 48.93% down on its pre-crash value of $45.13 and 30.24% down on the lowest point reached during the March crash when the stocks fell as low as $30.02.

If you had bought $1,000 worth of ACADIA Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $855.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $563.57.

ACADIA Pharmaceuticals stock price (NASDAQ:ACAD)

Use our graph to track the performance of ACAD stocks over time.

ACADIA Pharmaceuticals shares at a glance

Information last updated 2022-01-16.
Latest market close$23.05
52-week range$15.68 - $54.58
50-day moving average $21.77
200-day moving average $20.74
Wall St. target price$28.89
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.20

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

ACADIA Pharmaceuticals price performance over time

Historical closes compared with the close of $23.05 from 2022-01-14

1 week (2022-01-07) N/A
1 month (2021-12-16) -7.02%
3 months (2021-10-14) 29.35%
6 months (2021-07-17) -2.91%
1 year (2021-01-15) -57.04%
2 years (2020-01-17) -46.93%
3 years (2019-01-18) 9.40%
5 years (2017-01-18) 32.31

ACADIA Pharmaceuticals financials

Revenue TTM $474.4 million
Gross profit TTM $154.9 million
Return on assets TTM -11.58%
Return on equity TTM -31.35%
Profit margin -40.38%
Book value $3.53
Market capitalisation $3.7 billion

TTM: trailing 12 months

ACADIA Pharmaceuticals share dividends

We're not expecting ACADIA Pharmaceuticals to pay a dividend over the next 12 months.

ACADIA Pharmaceuticals share price volatility

Over the last 12 months, ACADIA Pharmaceuticals's shares have ranged in value from as little as $15.68 up to $54.5792. A popular way to gauge a stock's volatility is its "beta".

ACAD.US volatility(beta: 0.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ACADIA Pharmaceuticals's is 0.6087. This would suggest that ACADIA Pharmaceuticals's shares are less volatile than average (for this exchange).

ACADIA Pharmaceuticals overview

ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. .

Stocks similar to ACADIA Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site